Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Agile Therap (AGRX)

Agile Therap (AGRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 322,130
  • Shares Outstanding, K 87,298
  • Annual Sales, $ 0 K
  • Annual Income, $ -18,610 K
  • 60-Month Beta 1.48
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.00

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.18
  • Number of Estimates 3
  • High Estimate -0.18
  • Low Estimate -0.18
  • Prior Year -0.08
  • Growth Rate Est. (year over year) -125.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.67 +42.32%
on 09/04/20
3.89 -2.31%
on 09/15/20
+0.96 (+33.80%)
since 08/18/20
3-Month
2.32 +63.79%
on 07/29/20
3.89 -2.31%
on 09/15/20
+1.03 (+37.18%)
since 06/18/20
52-Week
0.35 +985.71%
on 10/29/19
4.77 -20.26%
on 02/12/20
+2.51 (+194.57%)
since 09/18/19

Most Recent Stories

More News
Agile Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 22nd Annual Global Investment Virtual Conference

Agile Therapeutics, Inc. (Nasdaq: AGRX), a forward-thinking women's healthcare company, today announced that Al Altomari, Chairman and Chief Executive Officer, will participate in a fireside chat at the...

AGRX : 3.80 (+2.98%)
Agile Therapeutics Announces Virtual Investor/Analyst Day on Monday, September 21, 2020

Company to Present Twirla Commercial Plan

AGRX : 3.80 (+2.98%)
Agile Therapeutics Launches I'm So Done Campaign to Inspire Women to Take an Active Role in Choosing their Birth Control

Visit BirthControlDoneMyWay.com to learn more about some of the many available contraceptive options

AGRX : 3.80 (+2.98%)
Agile Therapeutics Strengthens Executive Leadership Team with the Appointment of Paul Korner, MD, MBA, as Chief Medical Officer

Agile Therapeutics, Inc. (Nasdaq: AGRX), a forward-thinking women's healthcare company, today announced the appointment of Paul Korner, MD, MBA, to the position of Chief Medical Officer. Dr. Korner is...

AGRX : 3.80 (+2.98%)
Agile Therapeutics: 2Q Earnings Snapshot

PRINCETON, N.J. (AP) _ Agile Therapeutics Inc. (AGRX) on Tuesday reported a loss of $10.8 million in its second quarter.

AGRX : 3.80 (+2.98%)
Agile Therapeutics to Participate in Maxim Group's Leading Innovators in Women's Health Virtual Conference

Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Al Altomari, Chairman and Chief Executive Officer, will participate in a panel discussion as part of Maxim Group's...

AGRX : 3.80 (+2.98%)
Agile Therapeutics Reports Second Quarter 2020 Financial Results

Twirla on Track for Commercial Launch in Fourth Quarter 2020

AGRX : 3.80 (+2.98%)
How Agile Therapeutics (AGRX) Stock Stands Out in a Strong Industry

Agile Therapeutics (AGRX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

AGRX : 3.80 (+2.98%)
Agile Therapeutics to Join Russell 3000(R) and 2000(R) Indexes

Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that the Company will be added to the Russell 3000(R) and 2000(R) Indexes, effective after the U.S. market opens on...

AGRX : 3.80 (+2.98%)
Agile Therapeutics to Participate in Virtual Fireside Chat as part of the 2020 RBC Capital Markets Global Healthcare Conference on Wednesday, May 20, 2020

Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Al Altomari, Chairman and Chief Executive Officer, will participate in a virtual fireside chat as part of the...

AGRX : 3.80 (+2.98%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade AGRX with:

Business Summary

Agile Therapeutics, Inc. is a women's health specialty pharmaceutical company. It is focused on the development and commercialization of new prescription contraceptive products. The Company's lead product candidate is Twirla (TM), also known as AG200-15, a once-weekly prescription contraceptive patch...

See More

Key Turning Points

2nd Resistance Point 3.93
1st Resistance Point 3.86
Last Price 3.80
1st Support Level 3.71
2nd Support Level 3.63

See More

52-Week High 4.77
Last Price 3.80
Fibonacci 61.8% 3.08
Fibonacci 50% 2.56
Fibonacci 38.2% 2.04
52-Week Low 0.35

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar